. 2023 Feb 23;69(3):101427.
doi: 10.1016/j.neuchi.2023.101427.
Online ahead of print.
Affiliations
Affiliations
- 1 Department of Orthopedics, Orthopedic Research Institute, West China Hospital, Sichuan University, No. 37 Guo Xue Road, Chengdu 610041, China.
- 2 Department of Orthopedics, Orthopedic Research Institute, West China Hospital, Sichuan University, No. 37 Guo Xue Road, Chengdu 610041, China. Electronic address: [email protected].
Free article
Item in Clipboard
Y Luo et al.
Neurochirurgie.
.
Free article
Display options
Format
. 2023 Feb 23;69(3):101427.
doi: 10.1016/j.neuchi.2023.101427.
Online ahead of print.
Affiliations
- 1 Department of Orthopedics, Orthopedic Research Institute, West China Hospital, Sichuan University, No. 37 Guo Xue Road, Chengdu 610041, China.
- 2 Department of Orthopedics, Orthopedic Research Institute, West China Hospital, Sichuan University, No. 37 Guo Xue Road, Chengdu 610041, China. Electronic address: [email protected].
Item in Clipboard
Display options
Format
Abstract
Giant cell tumors (GCTs) of the bone are locally aggressive primary bone tumors with a benign character. Spinal involvement is rare which accounts for approximately 5% of all primary bone tumors and it is quite rare in the lumbar spine. An 11-year-old boy patient presented with pain of low back and bilateral low extremities. Lumbar CT and MRI revealed a lytic lesion of the L4 vertebra corpus. The patient earned remarkable and timely recovery with 2 surgical interventions and the use of denosumab. Surgical resection for GCTs is still preferable as the initial treatment, denosumab should be utilized after tumor resection whether based on the purpose of prevention or treatment of tumor recurrence.
Keywords:
Case report; Denosumab; Fusion; Giant cell tumor (GCT); Spine.
Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Similar articles
-
Sustained long-term complete regression of a giant cell tumor of the spine after treatment with denosumab.
Mattei TA, Ramos E, Rehman AA, Shaw A, Patel SR, Mendel E.
Mattei TA, et al.
Spine J. 2014 Jul 1;14(7):e15-21. doi: 10.1016/j.spinee.2014.02.019. Epub 2014 Feb 15.
Spine J. 2014.PMID: 24534393
-
Recurrent giant cell tumour of the thoracic spine managed by total en bloc spondylectomy and denosumab therapy: a case report.
Duan PG, Sheng YH, Deng CH, Tang BY, Yao HQ.
Duan PG, et al.
BMC Musculoskelet Disord. 2020 Feb 15;21(1):105. doi: 10.1186/s12891-020-3129-4.
BMC Musculoskelet Disord. 2020.PMID: 32061254
Free PMC article. -
Giant cell tumor of the thoracic spine causing acute paraplegia-a case report.
Lucasti C, Patel D, Hawayek B, Maraschiello M, Kowalski J.
Lucasti C, et al.
J Spine Surg. 2021 Jun;7(2):208-213. doi: 10.21037/jss-20-652.
J Spine Surg. 2021.PMID: 34296034
Free PMC article. -
Denosumab Treatment for a Residual Giant Cell Tumor of the Clivus: A Case Report and Review of the Literature.
Huh A, Villelli N, Martinez D, Ting J, Birhiray R, Payner TD, Kulwin CG.
Huh A, et al.
World Neurosurg. 2018 Oct;118:98-101. doi: 10.1016/j.wneu.2018.06.242. Epub 2018 Aug 3.
World Neurosurg. 2018.PMID: 30010069
Review.
-
Role of Denosumab in Endoscopic Endonasal Treatment for Juvenile Clival Giant Cell Tumor: A Case Report and Review of the Literature.
Inoue A, Ohnishi T, Kohno S, Nishikawa M, Nishida N, Ohue S.
Inoue A, et al.
World Neurosurg. 2016 Jul;91:674.e1-6. doi: 10.1016/j.wneu.2016.04.054. Epub 2016 Apr 23.
World Neurosurg. 2016.PMID: 27113403
Review.
Cite